Practice Updates in Adjuvant Immune Checkpoint Inhibition for Bladder Cancer
Matthew Galsky, MD, discusses how recent updates in adjuvant immune checkpoint inhibition for bladder cancer emphasize the integration of agents like pembrolizumab and atezolizumab, showing improved disease-free survival post cystectomy. Ongoing trials aim to refine treatment regimens and patient selection.
EP. 1: MIUC: Risk of Recurrence After Radical Cystectomy
March 12th 2025An expert discusses how patients with muscle-invasive urothelial carcinoma (MIUC) undergoing radical cystectomy face a significant recurrence risk. High-risk factors include advanced stage, lymph node involvement, and positive surgical margins. Neoadjuvant cisplatin-based chemotherapy can improve survival but does not eliminate recurrence risk. Other predictors include lymphovascular invasion, variant histology, and systemic inflammation markers.
Watch
EP. 2: High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy
March 12th 2025An expert discusses how adjuvant therapy options for high-risk muscle-invasive bladder cancer (MIBC); ypT2-ypT4a or N+) include cisplatin-based chemotherapy, which improves survival by targeting micrometastatic disease. Immune checkpoint inhibitors, such as atezolizumab and nivolumab, offer alternatives for cisplatin-ineligible patients.
Watch
